
While Ginkgo Bioworks Holdings Inc’s (NYSE:DNA) overall first-quarter results were better than expected, revenues and active programs in its core Foundry segment fell short of estimates, according to BofA Securities.
The Ginkgo Bioworks Analyst: Derik de Bruin downgraded the rating for Ginkgo Bioworks from Neutral to Underperform, while reducing the price target from $6 to $3.